Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Design, synthesis, and evaluation of inhibitors of cathepsin L: Exploiting a unique thiocarbazate chemotype.

Myers MC, Shah PP, Beavers MP, Napper AD, Diamond SL, Smith AB 3rd, Huryn DM.

Bioorg Med Chem Lett. 2008 Jun 15;18(12):3646-51. doi: 10.1016/j.bmcl.2008.04.065. Epub 2008 May 1.

2.

Identification and synthesis of a unique thiocarbazate cathepsin L inhibitor.

Myers MC, Shah PP, Diamond SL, Huryn DM, Smith AB 3rd.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):210-4. Epub 2007 Nov 1.

3.

Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L.

Shah PP, Myers MC, Beavers MP, Purvis JE, Jing H, Grieser HJ, Sharlow ER, Napper AD, Huryn DM, Cooperman BS, Smith AB 3rd, Diamond SL.

Mol Pharmacol. 2008 Jul;74(1):34-41. doi: 10.1124/mol.108.046219. Epub 2008 Apr 10.

4.

Design, synthesis and biological evaluation of a library of thiocarbazates and their activity as cysteine protease inhibitors.

Liu Z, Myers MC, Shah PP, Beavers MP, Benedetti PA, Diamond SL, Smith AB 3rd, Huryn DM.

Comb Chem High Throughput Screen. 2010 May;13(4):337-51.

5.

Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex.

Tsuge H, Nishimura T, Tada Y, Asao T, Turk D, Turk V, Katunuma N.

Biochem Biophys Res Commun. 1999 Dec 20;266(2):411-6.

PMID:
10600517
6.

Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1' substituents.

Altmann E, Green J, Tintelnot-Blomley M.

Bioorg Med Chem Lett. 2003 Jun 16;13(12):1997-2001.

PMID:
12781182
7.

Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.

Alper PB, Liu H, Chatterjee AK, Nguyen KT, Tully DC, Tumanut C, Li J, Harris JL, Tuntland T, Chang J, Gordon P, Hollenbeck T, Karanewsky DS.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1486-90. Epub 2006 Jan 18.

PMID:
16412634
8.

Discovery of selective and nonpeptidic cathepsin S inhibitors.

Irie O, Ehara T, Iwasaki A, Yokokawa F, Sakaki J, Hirao H, Kanazawa T, Teno N, Horiuchi M, Umemura I, Gunji H, Masuya K, Hitomi Y, Iwasaki G, Nonomura K, Tanabe K, Fukaya H, Kosaka T, Snell CR, Hallett A.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):3959-62. doi: 10.1016/j.bmcl.2008.06.009. Epub 2008 Jun 10.

PMID:
18572405
10.

Aziridide-based inhibitors of cathepsin L: synthesis, inhibition activity, and docking studies.

Vicik R, Busemann M, Gelhaus C, Stiefl N, Scheiber J, Schmitz W, Schulz F, Mladenovic M, Engels B, Leippe M, Baumann K, Schirmeister T.

ChemMedChem. 2006 Oct;1(10):1126-41.

PMID:
16933358
11.

Solid-phase synthesis of a combinatorial array of 1,3-bis(acylamino)-2-butanones, inhibitors of the cysteine proteases cathepsins K and L.

Yamashita DS, Dong X, Oh HJ, Brook CS, Tomaszek TA, Szewczuk L, Tew DG, Veber DF.

J Comb Chem. 1999 May-Jun;1(3):207-15.

PMID:
10746010
12.

Peptidomimetic 2-cyanopyrrolidines as potent selective cathepsin L inhibitors.

Yadav MR, Shinde AK, Chouhan BS, Giridhar R, Menard R.

J Enzyme Inhib Med Chem. 2008 Apr;23(2):190-7. doi: 10.1080/14756360701504842 .

PMID:
18343903
13.

Acyclic cyanamide-based inhibitors of cathepsin K.

Barrett DG, Deaton DN, Hassell AM, McFadyen RB, Miller AB, Miller LR, Payne JA, Shewchuk LM, Willard DH Jr, Wright LL.

Bioorg Med Chem Lett. 2005 Jun 15;15(12):3039-43.

PMID:
15896958
14.

Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K.

Marquis RW, Ru Y, Yamashita DS, Oh HJ, Yen J, Thompson SK, Carr TJ, Levy MA, Tomaszek TA, Ijames CF, Smith WW, Zhao B, Janson CA, Abdel-Meguid SS, D'Alessio KJ, McQueney MS, Veber DF.

Bioorg Med Chem. 1999 Apr;7(4):581-8.

PMID:
10353637
15.

Design and synthesis of 6-substituted amino-4-oxa-1-azabicyclo[3,2,0]heptan-7-one derivatives as cysteine proteases inhibitors.

Zhou NE, Guo D, Kaleta J, Purisima E, Menard R, Micetich RG, Singh R.

Bioorg Med Chem Lett. 2002 Dec 2;12(23):3413-5.

PMID:
12419373
16.

Azepanone-based inhibitors of human cathepsin L.

Marquis RW, James I, Zeng J, Trout RE, Thompson S, Rahman A, Yamashita DS, Xie R, Ru Y, Gress CJ, Blake S, Lark MA, Hwang SM, Tomaszek T, Offen P, Head MS, Cummings MD, Veber DF.

J Med Chem. 2005 Nov 3;48(22):6870-8.

PMID:
16250645
17.

Molecular docking of cathepsin L inhibitors in the binding site of papain.

Beavers MP, Myers MC, Shah PP, Purvis JE, Diamond SL, Cooperman BS, Huryn DM, Smith AB 3rd.

J Chem Inf Model. 2008 Jul;48(7):1464-72. doi: 10.1021/ci800085c. Epub 2008 Jul 4. Erratum in: J Chem Inf Model. 2010 Dec 27;50(12):2274.

18.

Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.

Falgueyret JP, Oballa RM, Okamoto O, Wesolowski G, Aubin Y, Rydzewski RM, Prasit P, Riendeau D, Rodan SB, Percival MD.

J Med Chem. 2001 Jan 4;44(1):94-104.

PMID:
11141092
19.

Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.

Tavares FX, Boncek V, Deaton DN, Hassell AM, Long ST, Miller AB, Payne AA, Miller LR, Shewchuk LM, Wells-Knecht K, Willard DH Jr, Wright LL, Zhou HQ.

J Med Chem. 2004 Jan 29;47(3):588-99.

PMID:
14736240
20.

Conserved cystatin segments as models for designing specific substrates and inhibitors of cysteine proteinases.

Lalmanach G, Serveau C, Brillard-Bourdet M, Chagas JR, Mayer R, Juliano L, Gauthier F.

J Protein Chem. 1995 Nov;14(8):645-53.

PMID:
8747425
Items per page

Supplemental Content

Write to the Help Desk